GOVXGeoVax, Inc.Running, no new patients
SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer
COVID-19 Infection · Hematopoietic and Lymphoid System Neoplasm · Leukemia · Lymphoma · Plasma Cell Myeloma
15Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +14.8
A key executive is leaving
Since Nov 6, 2026 · was worth 15, fading over time
Worry score15
Score over time
- Stage
- Phase 2
- Patients
- 63 (final count)
- Started
- Sep 27, 2021
- Main results expected
- Dec 31, 2026
- Fully finished
- Dec 31, 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Biological response
Measured over: At 28 days post the second vaccine injection
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- key_exec_departure: base 15, now 14.8, since 2026-11-06, fades (half-life) · source filing
Raw record changes
- none yet
Trial ID NCT04977024 · record last updated 2026-02-11 · checked 2026-11-09 15:47 UTC